K Sahakyan1, K E Lee, A Shankar, R Klein. 1. Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, 610 N Walnut Street, 4th Floor WARF, Madison, WI 53726, USA. sahakyan@epi.ophth.wisc.edu
Abstract
AIMS/HYPOTHESIS: To examine the association of serum cystatin C with the incidence of type 2 diabetes mellitus over a 15 year follow-up period. METHODS: The 15 year cumulative incidence of diabetes was measured in a cohort of Beaver Dam Eye Study participants (n = 3,472, 1988-2003). A person was defined as developing diabetes (a positive history of diabetes mellitus treated with insulin, oral hypoglycaemic agents and/or diet, or elevations in glycosylated haemoglobin levels) in the absence of diabetes at baseline. The relation of cystatin C and other risk factors to incident type 2 diabetes was determined using discrete time extension of the proportional hazards model. RESULTS: The 15 year cumulative incidence of diabetes was estimated to be 9.6%. After controlling for age, sex, body mass index, smoking status, glycosylated haemoglobin, proteinuria, chronic kidney disease status and hypertension status, serum cystatin C at baseline was associated with the 15 year cumulative incidence of type 2 diabetes (OR per log of cystatin C unit 2.19, 95% CI 1.02-4.68). CONCLUSIONS/ INTERPRETATION: These findings show a positive relationship of serum cystatin C levels with the incidence of type 2 diabetes mellitus independently of confounding risk factors. The findings strongly suggest the need for further evaluation of the potential importance of cystatin C in the pathogenesis of type 2 diabetes mellitus.
AIMS/HYPOTHESIS: To examine the association of serum cystatin C with the incidence of type 2 diabetes mellitus over a 15 year follow-up period. METHODS: The 15 year cumulative incidence of diabetes was measured in a cohort of Beaver Dam Eye Study participants (n = 3,472, 1988-2003). A person was defined as developing diabetes (a positive history of diabetes mellitus treated with insulin, oral hypoglycaemic agents and/or diet, or elevations in glycosylated haemoglobin levels) in the absence of diabetes at baseline. The relation of cystatin C and other risk factors to incident type 2 diabetes was determined using discrete time extension of the proportional hazards model. RESULTS: The 15 year cumulative incidence of diabetes was estimated to be 9.6%. After controlling for age, sex, body mass index, smoking status, glycosylated haemoglobin, proteinuria, chronic kidney disease status and hypertension status, serum cystatin C at baseline was associated with the 15 year cumulative incidence of type 2 diabetes (OR per log of cystatin C unit 2.19, 95% CI 1.02-4.68). CONCLUSIONS/ INTERPRETATION: These findings show a positive relationship of serum cystatin C levels with the incidence of type 2 diabetes mellitus independently of confounding risk factors. The findings strongly suggest the need for further evaluation of the potential importance of cystatin C in the pathogenesis of type 2 diabetes mellitus.
Authors: E Coll; A Botey; L Alvarez; E Poch; L Quintó; A Saurina; M Vera; C Piera; A Darnell Journal: Am J Kidney Dis Date: 2000-07 Impact factor: 8.860
Authors: Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy Journal: JAMA Date: 2004-02-18 Impact factor: 56.272
Authors: Christos Tikellis; Peter J Wookey; Riccardo Candido; Sof Andrikopoulos; Merlin C Thomas; Mark E Cooper Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: Hien Pham; Cassianne Robinson-Cohen; Mary L Biggs; Joachim H Ix; Kenneth J Mukamal; Linda F Fried; Bryan Kestenbaum; David S Siscovick; Ian H de Boer Journal: Clin J Am Soc Nephrol Date: 2012-03-01 Impact factor: 8.237
Authors: Barbara E K Klein; Kerri P Howard; Ronald E Gangnon; Jennifer O Dreyer; Kristine E Lee; Ronald Klein Journal: JAMA Date: 2012-12-19 Impact factor: 56.272